Biblio
Export 794 results:
Author Title Type [ Year
Filters: First Letter Of Last Name is V [Clear All Filters]
“The Effectiveness of GRADIOR: A Neuropsychological Rehabilitation Program for People with Mild Cognitive Impairment and Mild Dementia. Results of a Randomized Controlled Trial After 4 and 12 Months of Treatment.”, J Alzheimers Dis, vol. 86, no. 2, pp. 711-727, 2022.
, “Impact of COVID-19 on 'Living Well' with Mild-to-Moderate Dementia in the Community: Findings from the IDEAL Cohort.”, J Alzheimers Dis, vol. 85, no. 2, pp. 925-940, 2022.
, “Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study.”, J Alzheimers Dis, vol. 90, no. 4, pp. 1739-1747, 2022.
, “Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study.”, J Alzheimers Dis, vol. 90, no. 4, pp. 1739-1747, 2022.
, “Improved Alzheimer's Disease versus Frontotemporal Lobar Degeneration Differential Diagnosis Combining EEG and Neurochemical Biomarkers: A Pilot Study.”, J Alzheimers Dis, vol. 90, no. 4, pp. 1739-1747, 2022.
, “Increased Functional Connectivity of the Precuneus in Individuals with a Family History of Alzheimer's Disease.”, J Alzheimers Dis, vol. 91, no. 2, pp. 559-571, 2022.
, “Insulin-Like Growth Factor, Inflammation, and MRI Markers of Alzheimer's Disease in Predominantly Middle-Aged Adults.”, J Alzheimers Dis, vol. 88, no. 1, pp. 311-32, 2022.
, “Interaction Between Diet and Microbiota in the Pathophysiology of Alzheimer's Disease: Focus on Polyphenols and Dietary Fibers.”, J Alzheimers Dis, vol. 86, no. 3, pp. 961-982, 2022.
, “A Novel Panel of Plasma Proteins Predicts Progression in Prodromal Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 549-561, 2022.
, “Obesity-Associated Neurodegeneration Pattern Mimics Alzheimer's Disease in an Observational Cohort Study.”, J Alzheimers Dis, vol. 91, no. 3, pp. 1059-1071, 2022.
, “Polygenic Scores of Alzheimer's Disease Risk Genes Add Only Modestly to APOE in Explaining Variation in Amyloid PET Burden.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1615-1625, 2022.
, “Potential Mechanisms Underlying Resistance to Dementia in Non-Demented Individuals with Alzheimer's Disease Neuropathology.”, J Alzheimers Dis, vol. 87, no. 1, pp. 51-81, 2022.
, “Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis.”, J Alzheimers Dis, vol. 88, no. 1, pp. 229-239, 2022.
, “Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis.”, J Alzheimers Dis, vol. 88, no. 1, pp. 229-239, 2022.
, “Pre-Diagnostic Symptoms of Young-Onset Dementia in the General Practice up to Five Years Before Diagnosis.”, J Alzheimers Dis, vol. 88, no. 1, pp. 229-239, 2022.
, “Progression from Subjective Cognitive Decline to Mild Cognitive Impairment or Dementia: The Role of Baseline Cognitive Performance.”, J Alzheimers Dis, vol. 86, no. 4, pp. 1763-1774, 2022.
, “Proteomic Profiles of Neurodegeneration Among Mexican Americans and Non-Hispanic Whites in the HABS-HD Study.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1243-1254, 2022.
, “Relationship Between the Gut Microbiota and Alzheimer's Disease: A Systematic Review.”, J Alzheimers Dis, vol. 87, no. 2, pp. 519-528, 2022.
, “Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 89, no. 3, pp. 943-954, 2022.
, “Rheumatoid Arthritis, Cognitive Impairment, and Neuroimaging Biomarkers: Results from the Mayo Clinic Study of Aging.”, J Alzheimers Dis, vol. 89, no. 3, pp. 943-954, 2022.
, “Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.”, J Alzheimers Dis, vol. 87, no. 1, pp. 101-129, 2022.
, “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
, “Systemic Injection of Aged Blood Plasma in Adult C57BL/6 Mice Induces Neurophysiological Impairments in the Hippocampal CA1.”, J Alzheimers Dis, vol. 89, no. 1, pp. 283-297, 2022.
, “Visually Identified Tau 18F-MK6240 PET Patterns in Symptomatic Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 4, pp. 1627-1637, 2022.
, “Accelerometer-Measured, Habitual Physical Activity and Circulating Brain-Derived Neurotrophic Factor: A Cross-Sectional Study.”, J Alzheimers Dis, vol. 85, no. 2, pp. 805-814, 2021.
,